Benjamin J. Hindson - Aug 2, 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol
TXG
Transactions as of
Aug 2, 2021
Transactions value $
-$7,347,147
Form type
4
Date filed
8/4/2021, 04:45 PM
Previous filing
Jul 6, 2021
Next filing
Aug 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $13.3K +11.1K +23.42% $1.20* 58.6K Aug 2, 2021 Direct F1
transaction TXG Class A Common Stock Options Exercise $154K +30.6K +52.17% $5.04* 89.1K Aug 2, 2021 Direct F1
transaction TXG Class A Common Stock Sale -$1.05M -5.9K -6.62% $178.25 83.2K Aug 2, 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale -$1.44M -8.05K -9.67% $179.08 75.2K Aug 2, 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale -$1.93M -10.7K -14.25% $180.13 64.5K Aug 2, 2021 Direct F1, F4
transaction TXG Class A Common Stock Sale -$1.59M -8.8K -13.65% $181.13 55.7K Aug 2, 2021 Direct F1, F5
transaction TXG Class A Common Stock Sale -$946K -5.2K -9.34% $181.98 50.5K Aug 2, 2021 Direct F1, F6
transaction TXG Class A Common Stock Sale -$329K -1.8K -3.57% $183.02 48.7K Aug 2, 2021 Direct F1, F7
transaction TXG Class A Common Stock Sale -$147K -800 -1.64% $184.02 47.9K Aug 2, 2021 Direct F1, F8
transaction TXG Class A Common Stock Sale -$74K -400 -0.84% $184.95 47.5K Aug 2, 2021 Direct F1, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -11.1K -15.64% $0.00 60K Aug 2, 2021 Class A Common Stock 11.1K $1.20 Direct F1, F10
transaction TXG Stock Option (right to buy) Options Exercise $0 -30.6K -17.46% $0.00 144K Aug 2, 2021 Class A Common Stock 30.6K $5.04 Direct F1, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $177.63 to $178.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $178.63 to $179.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $179.63 to $180.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $180.63 to $181.625. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 This transaction was executed in multiple trades at prices ranging from $181.63 to $182.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7 This transaction was executed in multiple trades at prices ranging from $182.63 to $183.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F8 This transaction was executed in multiple trades at prices ranging from $183.66 to $184.595. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F9 This transaction was executed in multiple trades at prices ranging from $184.84 to $184.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F10 This option, originally for 200,000 shares, of which 140,032 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F11 This option, originally for 175,000 shares, of which 30,552 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Chief Scientific Officer and President